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sefulness  of  an speciﬁc  out patient  clinic  on  hereditary
idney diseases:  A  different  approach  based  on  the family
ree
tilidad  de  una  consulta  de  enfermedades  renales  hereditarias:
n  enfoque  diferente  basado  en  el  árbol  genealógico
íctor Martínez Jiménez ∗, Fernanda Ramos Carrasco, Concepción Alcázar Fajardo, Juan
ernardo  Cabezuelo Romero
ervicio de Nefrología, Hospital Reína Sofía, Murcia, Spainereditary kidney diseases (HKDs) are a heterogeneous group
f kidney diseases that account for 10% to 15% of patients
ho  start renal replacement therapy (RRT), and could account
or an even greater percentage in the paediatric population.1
KDs require a diagnostic approach that is different from
ther nephropaties since its pathogenesis is due to a mutation.
he diagnosis goes beyond the affected patients, it includes
he family. Ait is necessary to construct a family tree including
oth affected and non affected individuals.
Autosomal dominant polycystic kidney disease (ADPKD),
hich is due to a mutation in the PKD1 or PKD22 gene, is
he most common hereditary kidney disease and accounts for
–10% of patients in RRT. It is characterised by the growth of
idney cysts that lead to a decline in kidney function until
RT is required.3 In addition, it is associated with other mani-
4estations: hypertension (HTN), polycystic liver disease, brain
neurysms and valve diseases.5 Alport syndrome (AS) is clas-
iﬁed according to its pattern of inheritance: 85% X-linked
wing to a mutation in COL4A56 and 15% autosomal recessive
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Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)owing to a mutation in COL4A3 or COL4A4.7 In AS, an abnormal
glomerular basement membrane causes microhaematuria,
proteinuria and progressive CKD, which may be associated
with eye abnormalities and hearing loss.8 Benign familial
microhaematuria (BFM), which may affect up to 1% of the
population, and recessive AS have a common pathogenesis.9
Tubulopathies are another group of HKDs, by which the muta-
tion of a protein involved in tubular reabsorption fosters the
excretion of certain ions in the urine.10 In addition, there are
other hereditary syndromes with kidney disease in a con-
text of signiﬁcant multi-organ involvement such as tuberous
sclerosis11 and Bardet–Biedl syndrome.12
Our objective was to create a speciﬁc practice for the follow-
up of patients with HKD. These diseases tend not to be very
prevalent, and so it is necessary to group them in a practiceázar Fajardo C, Cabezuelo Romero JB. Utilidad de una consulta de
árbol genealógico. Nefrología. 2016;36:217–221.
followed up by the same physician to increase his or her
clinical experience. Below we present the steps that we  fol-
lowed, the difﬁculties that arose and our results after 3 years of
follow-up.
vier Espan˜a, S.L.U. This is an open access article under the CC
.
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Study  design  and  patient  screening
In February 2012, a speciﬁc practice was created for the follow-
up of patients with HKD in our department, which covers
a population of nearly 300,000 inhabitants and has approxi-
mately 1500 outpatient visits per year. Our hospital is a tertiary
hospital. Patients with kidney disease and a prior family his-
tory with a high clinical probability of HKD or with a positive
genetic test were enrolled. Patients with a glomerular ﬁltration
rate lower than 25 ml/min were excluded.
Patients were referred from Primary Care, Paediatric
Nephrology and other Nephrology practices and by other
specialists to an HKD-speciﬁc practice followed up by the
same nephrologist. They were discharged from this practice if
HKD was ruled out, and relatives with kidney diseases were
enrolled after careful screening was performed. Follow-up
lasted 3 years. The study ended in January 2015 (Fig. 1).
All the patients underwent blood and urine testing, a
kidney ultrasound, measurement of blood pressure and prepa-
ration of a family tree that gathered family relationships with
proband, healthy relatives and relatives with kidney disease
(microhaematuria, proteinuria, kidney cysts, chronic kidney
disease and requirement for RRT). With these data, 3 basic
clinical patterns were established: tubulointerstitial, subdi-
vided into cystic (cystic diseases by ultrasound diagnosis) and
tubulopathic (ion abnormalities due to increase in urinary
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Fig. 1 – Hereditary kidney disease out patient clinic planning. AD
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excretion); glomerular (proteinuria and microhaematuria);
and syndromic (kidney disease in a context of signiﬁcant
multi-organ abnormality). The clinical patterns, together with
the pattern of inheritance (autosomal dominant [AD], auto-
somal recessive [AR] and linked to the X chromosome [XL]),
guided the physician towards an initial suspected clinical
diagnosis in each patient (Fig. 1).
At the end of the study, the following data were collected:
age, gender, performance of a kidney biopsy or genetic study,
departments having referred the patient to the HKD practice,
existence of a prior diagnosis, follow-up by other specialists
owing to his or her HKD, performance of complete family
screening, HTN, treatment with renin–angiotensin system
inhibitors, diabetes mellitus, dyslipidaemia and whether the
subject was a smoker.
In ADPKD, there was no radiologist assigned speciﬁcally to
analyse ultrasound data: kidney size measured in centime-
tres, description of normal or large kidneys and presence
of liver cysts. Familial microhaematuria (FM) was deﬁned
as microhaematuria in the patient and at least one of his
or her relatives, other causes having been ruled out with
immunology, serology and lithiasis studies. The following
were included within FM:  AS by consistent genetic or histolog-
ical diagnosis and familial IgA nephropathy by kidney biopsy
with a positive family history. In this group, the hearing tests
performed were assessed by the otorhinolaryngologist as nor-
mal  or with hearing loss.
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Prevalence of hereditary kidney diseases
Familial microhaematuria: 59 (33%)
–6 XLAS
–2 ARAS
–3 FIgAN
–48 FMH
–3 Cys
–3 TS –2 BB
Unknown: 8 (5%)
Autosomal dominant
polycystic kidney disease:
90 (55%)
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–2 DD
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Tubulopathies: 15 (8%)
Fig. 2 – Prevalence of hereditary kidney diseases at the end of the study (number of patients and percentage). BB,
Bardet–Biedl syndrome; Cys, cystinuria; TS, tuberous sclerosis; ADH, autosomal dominant hypocalcaemia; ADHm,
autosomal dominant hypomagnesae.
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iOf the 177 patients followed up in the HKD practice, 73
ere men  (41.2%) and 104 were women (58.8%). The mean
ge was: 43.13 ± 15.20 (14–84) years. A family tree was pre-
ared for all the patients; family screening was complete in 81
atients (45.8%) and incomplete in 96 patients (54.2%) owing to
heir relatives’ death or refusal. A total of 117 patients (66.1%)
ad at least one relative in RRT. Regarding patterns of inher-
tance: AD in 143 (80.1%), AR in 16 (9%), XL in 11 (6.2%) and
nknown in 7 (4%). A genetic study was requested in 34 cases
nd positive in 21 (61.8%). Of the 8 kidney biopsies performed,
nly 3 were diagnostic for IgA nephropathy, and the rest were
ormal. Fig. 2 shows the prevalence of HKD in our practice.
The origin of the patients followed up in the HKD practice
as: 61 (34.5%) from Primary Care; 14 (7.9%) from Paediatric
ephrology; 51 (28.8%) from other Nephrology practices; 17
9.6%) from other specialists, mainly Urology and Internal
edicine; and 34 (19.2%) from family screening performed
n the HKD practice. Only 73 patients (41.2%) were diagnosed
efore being referred to our practice.
A total of 49 patients (27.7%) were followed up by other spe-
ialists owing to abnormalities deriving from their HKD: 19
y Urology, owing to lithiasis, repeated urinary infections or
omplicated cysts; 11 by Otorhinolaryngology owing to hear-
ng loss; 5 by Cardiology owing to ischaemic cardiomyopathy
r mitral valve insufﬁciency; and 4 by Gastroenterology owing
o massive polycystic liver disease or diverticulosis.
An analysis of cardiovascular risk factors revealed that
4 patients (53.1%) were hypertensive, 15 (8.5%) were dia-
etic, 58 (32.8%) had dyslipidaemia and 42 (23.7%) were
mokers. In addition, 104 patients (58.8%) were treated with
enin–angiotensin system inhibitors.
The ultrasound data in the ADPKD group were as follows:
iver cysts were present in 49 patients (54.44%) and kidney size
as only measured in 45 (50%), although in all patients it was
etermined whether their kidneys were normal or large. Hear-
ng tests were performed in the group with FM in 45 patients
75%), 26 of whom had hearing loss and only 13 of whom were
nformed by the otorhinolaryngologist.The majority of patients were referred to our practice owing
to a suspicion of HKD, as they had kidney disease and at least
one relative in RRT, although nearly 60% were not initially diag-
nosed. To establish a clinical diagnosis, our main tool was not
the genetic study, but the family tree. In addition to examining
the patient, it is essential to perform comprehensive family
screening, with laboratory testing and a kidney ultrasound,
distinguishing between healthy individuals and individuals
with kidney disease to identify the type of inheritance and
clinical pattern. However, in half of the cases family screening
was incomplete owing to some family members’ refusal or
death.
Proper diagnosis of HKD is important for managing factors
for progression, establishing a multidisciplinary approach,
performing suitable recording, offering genetic counselling
and, in some cases, starting the appropriate treatment, such as
enzyme replacement in Fabry disease13 or everolimus in tuber-
ous sclerosis.14 However, there are familial kidney diseases of
unknown origin or with a very atypical clinical presentation
that are the subject of research studies, where collaboration
between hospitals is required to create a national network that
includes more  patients with these low-prevalence diseases.
The latest next-generation genomic sequencing techniques
are contributing to the evolution and optimisation of HKD
diagnosis.15
ADPKD is the most common hereditary kidney disease and
our data is consistent with this. Ultrasound is the technique
of choice for ADPKD diagnosis, in conjunction with follow-up
and screening in ﬁrst-degree relatives.16 Kidney volume is the
best predictor of disease progression.17 However, in half of the
cases in our radiological study, kidney size was not assessed
precisely. In addition, an ultrasound must be performed to
diagnose liver cysts, the most common extrarenal manifes-
tation of ADPKD.2 It is essential that awareness be raised and
that imaging tests be performed by a single physician trained
in these diseases.
Clinically, it is difﬁcult to distinguish between BFM, AS
carrier status and familial IgA, since they may have the
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same glomerular pattern.18 Although in our study they were
grouped together as FM, a deﬁnitive diagnosis should be made.
The ﬁrst step in making a differential diagnosis is determining
the pattern of inheritance: AD in BFM, AR or XL in AS and poly-
genic inheritance in familial IgA (although the genes involved
are being researched).19 A deﬁnitive diagnosis of AS is made
by ﬁnding a dysfunctional glomerular basement membrane
in electron microscopy or a pathogenic mutation in COL4A5
in XL Alport syndrome, or 2 pathogenic mutations in COL4A3
or COL4A4 in AR Alport syndrome, while in BFM there would
only be a mutation in COL4A3/COL4A4.9
There are characteristic multi-organ abnormalities asso-
ciated with certain HKDs that may help to identify them.
It is essential to take a multidisciplinary approach. In many
cases, the nephrologist becomes the coordinator of the other
specialties. Patients should be followed up by a single physi-
cian with experience so that these low-prevalence diseases do
not go undetected. If AS is suspected, a hearing test must be
performed to rule out bilateral hearing loss for high frequen-
cies (2000–8000 Hz).8 When we reviewed the hearing tests, we
found that hearing loss was only diagnosed in half of the cases,
as it was considered to be normal when the impairment was
mild: this is a confounding factor. Another added problem is
the transition from Paediatrics to Nephrology for adults, in
such a difﬁcult stage as adolescence, when the patient may
come to deny his or her disease and reject chronic treatment.20
There is a series of factors that accelerate a decline in
kidney function and they should be managed to slow down
its progression.21 The factors for progression of ADPKD are:
genetic (the PKD1 mutation has a worse prognosis than the
PKD2 mutation), kidney volume, HTN,5 proteinuria, inability
to concentrate urine and hyperuricaemia.22 The factors for
progression of AS are: type of mutation (truncating mutations
are more  serious), proteinuria, hearing loss and episodes of
macrohaematuria.23 Renin–angiotensin system inhibitors are
a ﬁrst-line treatment, as they manage HTN, decrease protein-
uria and delay a decline in kidney function in both ADPKD24
and AS.25
In conclusion, it is necessary to create an HKD practice
in which these types of kidney disease are followed up by a
single physician to ensure a suitable diagnostic and multi-
disciplinary approach, management of factors for progression
and collaboration between hospitals contributing to diagnos-
tic and therapeutic advances in this constantly evolving ﬁeld.
It is necessary to stress the importance of preparing a com-
plete family tree to classify the pattern of inheritance (AD, AR
or XL) and the type of kidney injury (cystic, tubular, glomerular
or syndromic), which, unlike genetic diagnosis, is available at
all hospitals.
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